Table 4 Univariate and multivariable analyses for association between patient characteristics and comorbidity
Variable | With comorbidity (n) | Without comorbidity (n) | Univariate | Multivariable | ||||
|---|---|---|---|---|---|---|---|---|
OR | 95Â % CI | p value | AOR* | 95 % CI | p value | |||
Age (continuous) median (IQR) | 46 (40–56) | 41 (35–49) | 1.05 | 1.03–1.06 | <0.001 |  |  |  |
Age category (years) | ||||||||
 18–≤35 | 30 (14.9 %) |  213 (25.6 %) | 1.00 |  |  |  |  |  |
 35–≤45 | 66 (32.8 %) | 340 (41.0 %) | 1.38 | 0.87–2.19 | 0.176 | 1.42 | 0.89–2.26 | 0.144 |
 45–≤55 | 54 (26.9 %) | 194 (23.4 %) | 1.98 | 1.21–3.22 | 0.006 | 2.25 | 1.37–3.69 | 0.001 |
 >55 | 51 (25.4 %) | 83 (10.0 %) | 4.36 | 2.60–7.32 | <0.001 | 5.42 | 3.17–9.26 | <0.001 |
Gender | ||||||||
 Male, no. (%) | 47 (23.2 %) | 269 (32.5 %) | 1.00 |  |  |  |  |  |
 Female, no. (%) | 156 (76.1 %) | 560 (67.5 %) | 1.59 | 1.12–2.28 | 0.010 | 2.12 | 1.45–3.11 | <0.001 |
Baseline CD4+ cell count ≥500, no (%) | 14 (6.9 %) | 42 (5.05 %) | 1.34 | 0.71–2.51 | 0.366 |  |  |  |
Latest CD4+ cell count ≥500, no (%) | 91 (44.8 %) | 323 (38.8 %) | 1.30 | 0.93–1.83 | 0.126 |  |  |  |
Baseline WHO stage | ||||||||
 I | 38 (21.2 %) | 196 (27.4 %) | 1.00 |  |  |  |  |  |
 II | 49 (27.4 %) | 157 (22.0 %) | 1.61 | 1.00–2.58 | 0.048 |  |  |  |
 III | 60 (33.5 %) | 270 (37.8 %) | 1.15 | 0.73–1.79 | 0.549 |  |  |  |
 IV | 32 (17.9 %) | 91 (12.7 %) | 1.81 | 1.07–3.09 | 0.028 |  |  |  |
Duration HIV (years) ≥7 | 109 (53.7 %) | 354 (42.6 %) | 1.59 | 1.14–2.22 | 0.006 |  |  |  |
Duration ART (years) | ||||||||
 <2, no. (%) | 38 (18.9 %) | 145 (18.0 %) | 1.00 |  |  |  |  |  |
 2–5 | 48 (23.9 %) | 214 (26.6 %) | 0.86 | 0.53–1.38 | 0.521 |  |  |  |
 >5 | 115 (57.2 %) | 445 (55.4 %) | 0.99 | 0.65–1.49 | 0.947 |  |  |  |
ART regimen | ||||||||
 D4T/3TC + EFV or NVP, no. (%) | 127 (62.5 %) | 498 (59.9 %) | 1.00 |  |  |  |  |  |
 PI-based | 10 (4.9 %) | 39 (4.7 %) | 1.01 | 0.49–2.07 | 0.988 |  |  |  |
 TDF/3TC + EFV or NVP | 39 (19.2 %) | 207 (24.9 %) | 0.76 | 0.45–1.27 | 0.294 |  |  |  |
 AZT/3TC + EFV or NVP | 27 (13.3 %) | 88 (10.6 %) | 1.20 | 0.75–1.93 | 0.444 |  |  |  |